TO THE EDITOR-We have read with interest the patient-level quantitative review of randomized trials for the treatment of invasive candidiasis by Andes et al [1] .
However, we do have some questions regarding the figures of included patients.
Andes et al report that all modified intent-to-treat (MITT) patients of the 7 analyzed trials were included. Excluded from analysis were cases with missing fungal species information and with multiple Candida species infection, as was one trial arm receiving combination therapy. It is unclear how the data of the sequential treatment arm (amphotericin B followed by fluconazole) in the randomized comparison with voriconazole were managed [2] .
In studying the original published trials, a total of 2224 MITT patients are detected, compared to only 1915 patients included in the Andes analysis (Table 1) . No explanation is provided as to why 309 patients were excluded from analysis; this is a significantly higher number than would be expected from the exclusion of patients infected with an unknown species or with multiple species. It is most remarkable that 254 patients treated with voriconazole were included, as the published data report 248 MITT voriconazole patients, including 12 patients infected with multiple species [2] . In addition, it struck us that only 541 patients treated with micafungin were analyzed, whereas the original studies included a total of 637 MITT patients treated with micafungin [7, 8] .
It is likely that the most obvious reason is the lack of data on the 30-day allcause mortality, as this was the primary outcome. However, the secondary outcome was clinical and microbiologic success at end of treatment. This outcome parameter should be known for all 2224 MITT patients of the 7 studies.
Clarification of these issues seems necessary as these analyses are used as corroborative evidence for the revision of guidelines in the treatment of invasive candidiasis. These tend increasingly toward favoring echinocandins in any patient and for a full course of therapy, which will induce a significant financial burden in several health systems.
